Keywords: AstraZeneca, Seroquel XR, German patent, Merck & Co, MK-0431E, Diabetes-cholesterol combo, Type 2 diabetes

Germany invalidates Seroquel patent; Merck drops combo diabetes drug development

Article | 14 November 2012

Print This

Anglo-Swedish drug major AstraZeneca (LSE: AZN) said last evening that the Federal Patent Court in Germany has found the formulation ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in